Markets:

Overview

News

Currencies

International

Treasuries

Imago BioSciences, Inc. - Common stock (NQ:IMGO)

N/A UNCHANGED

Last Price Updated: 4:00 PM EST, Jan 10, 2023 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Press Releases about Imago BioSciences, Inc. - Common stock

Merck Begins Tender Offer to Acquire Imago BioSciences, Inc.

December 12, 2022

From Merck & Co., Inc.

Via Business Wire

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations:) Apollo Endosurgery, Inc. (Nasdaq - APEN), Imago BioSciences, Inc. (Nasdaq - IMGO), Opiant Pharmaceuticals Inc. (Nasdaq - OPNT), Benefitfocus, Inc. (Nasdaq - BNFT)

December 05, 2022

From Brodsky & Smith LLC

Via GlobeNewswire

IMAGO BIOSCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Imago BioSciences, Inc. - IMGO

November 22, 2022

From Kahn Swick & Foti, LLC

Via Business Wire

TC BioPharm Ltd ($TCBP) leads fight against Acute myeloid leukemia with its cell therapy product OmnImmune

November 22, 2022

Via AB Newswire

Topics Death Economy Stocks

Imago BioSciences (NASDAQ: IMGO) to be Acquired by Merck (NYSE: MRK) for $1.35 Billion

November 21, 2022

Imago BioSciences, Inc. (NASDAQ: IMGO) is engaged as a clinical-stage biopharmaceutical company, which is focused on the research and development

Via Spotlight Growth

IMGO Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Imago BioSciences, Inc. Is Fair to Shareholders

November 21, 2022

From Halper Sadeh LLC

Via Business Wire

Merck to Acquire Imago BioSciences, Inc.

November 21, 2022

From Merck & Co., Inc.

Via Business Wire

Imago BioSciences Presents Positive Data from Ongoing Phase 2 Study of Bomedemstat in Essential Thrombocythemia at ASH 2021

December 12, 2021

From Imago BioSciences

Via Business Wire

Imago BioSciences Presents Positive Data from Ongoing Phase 2 Study of Bomedemstat in Advanced Myelofibrosis at ASH 2021

December 11, 2021

From Imago BioSciences, Inc.

Via Business Wire

Imago BioSciences Appoints Laurie Keating to Board of Directors

November 18, 2021

From Imago BioSciences, Inc.

Via Business Wire

Imago BioSciences Announces Oral Data Presentations at the Upcoming 63rd American Society of Hematology Annual Meeting and Exposition

November 04, 2021

From Imago BioSciences, Inc.

Via Business Wire

Imago BioSciences Announces Its Addition to the Russell 2000® Index

September 20, 2021

From Imago BioSciences, Inc.

Via Business Wire

Imago BioSciences Reports Second Quarter 2021 Financial Results and Provides Recent Business Updates

August 19, 2021

From Imago BioSciences, Inc.

Via Business Wire

Imago BioSciences Receives Orphan Designation From European Medicines Agency for Bomedemstat for the Treatment of Essential Thrombocythemia

July 30, 2021

From Imago BioSciences

Via Business Wire

Imago BioSciences, Inc. Announces Exercise of Underwriters’ Option to Purchase Additional Shares

July 26, 2021

From Imago BioSciences, Inc.

Via Business Wire

Imago BioSciences, Inc. Announces Closing of $134.4 Million Initial Public Offering

July 20, 2021

From Imago BioSciences, Inc.

Via Business Wire

Imago BioSciences, Inc. Announces Pricing of Upsized Initial Public Offering of Common Stock

July 15, 2021

From Imago BioSciences, Inc.

Via Business Wire

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.